119 related articles for article (PubMed ID: 22186617)
21. Treatment options for advanced pancreatic cancer: a review.
Warsame R; Grothey A
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
[TBL] [Abstract][Full Text] [Related]
22. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
23. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):359-62. PubMed ID: 23846927
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
27. Systemic treatment of advanced pancreatic cancer.
Heinemann V; Haas M; Boeck S
Cancer Treat Rev; 2012 Nov; 38(7):843-53. PubMed ID: 22226241
[TBL] [Abstract][Full Text] [Related]
28. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
29. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
30. Systemic therapy for metastatic pancreatic adenocarcinoma.
Lawrence B; Findlay M
Ther Adv Med Oncol; 2010 Mar; 2(2):85-106. PubMed ID: 21789129
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic adenocarcinoma: new strategies for success.
O'Reilly EM
Gastrointest Cancer Res; 2009 Mar; 3(2 Suppl):S11-5. PubMed ID: 19461915
[TBL] [Abstract][Full Text] [Related]
32. Metastatic pancreatic cancer: are we making progress in treatment?
Chiu J; Yau T
Gastroenterol Res Pract; 2012; 2012():898931. PubMed ID: 23304129
[TBL] [Abstract][Full Text] [Related]
33. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers.
Tada M; Nakai Y; Sasaki T; Hamada T; Nagano R; Mohri D; Miyabayashi K; Yamamoto K; Kogure H; Kawakubo K; Ito Y; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Isayama H; Omata M; Koike K
World J Clin Oncol; 2011 Mar; 2(3):158-63. PubMed ID: 21611090
[TBL] [Abstract][Full Text] [Related]
34. Erlotinib in the treatment of advanced pancreatic cancer.
Kelley RK; Ko AH
Biologics; 2008 Mar; 2(1):83-95. PubMed ID: 19707431
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics in chemotherapy for GI tract cancer.
Furuta T
J Gastroenterol; 2009; 44(10):1016-25. PubMed ID: 19728007
[TBL] [Abstract][Full Text] [Related]
36. Role of erlotinib in the management of pancreatic cancer.
Starling N; Neoptolemos J; Cunningham D
Ther Clin Risk Manag; 2006 Dec; 2(4):435-45. PubMed ID: 18360654
[TBL] [Abstract][Full Text] [Related]
37. Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.
Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
J Clin Oncol; 2023 Dec; 41(36):5482-5492. PubMed ID: 38100992
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic cancer: molecular pathogenesis and new therapeutic targets.
Wong HH; Lemoine NR
Nat Rev Gastroenterol Hepatol; 2009 Jul; 6(7):412-22. PubMed ID: 19506583
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
40. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes.
Sharaf RN; Butte AJ; Montgomery KD; Pai R; Dudley JT; Pasricha PJ
BMC Gastroenterol; 2011 Jan; 11():5. PubMed ID: 21251264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
